Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer
Latest Information Update: 02 Jul 2024
At a glance
- Drugs Anti MUC1 CAR T cell/PD-1 knockout engineered T cell therapy Guangzhou Anjie Biomedical Technology (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 17 Apr 2023 Status changed from recruiting to completed.
- 01 Oct 2019 New trial record